Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 3

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 3
---
 should carefully read this prospectus as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. The securities may be sold by us to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus and the comparable section of any applicable prospectus supplement. If any underwriters are involved in the sale of the securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in the applicable prospectus supplement. Our common stock is traded on the Nasdaq Capital Market under the symbol “INKT.” On November 6, 2025, the closing price of our common stock was $13.66. We have not yet determined whether the other securities that may be offered by this prospectus will be listed on any exchange, interdealer quotation system or over-the-countermarket. If we decide to seek the listing of any such securities upon issuance, the prospectus supplement relating to those securities will disclose the exchange, quotation system or market on which those securities will be listed. As of November 6, 2025, the aggregate market value of our outstanding common stock held by non-affiliates,or our public float, was approximately $35,031,699 based on 2,149,184 shares of outstanding common stock held by non-affiliatesas of such date, at a price of $16.30 per share on September 22, 2025, which was the highest closing sale price of our common stock on the Nasdaq Capital Market within 60 days of the filing date of this registration statement. During the prior 12 calendar month period that ends on and includes the date of this prospectus, we have offered and sold 163,660 shares of common stock for gross proceeds of $5,035,949 pursuant to General Instruction I.B.6 of Form S-3.Pursuant to General Instruction I.B.6 of Form S-3,in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-thirdof our public float in any 12-monthperiod so long as our public float remains below $75.0 million. Investing in our securities involves a high degree of risk. Risks associated with an investment in our